Last reviewed · How we verify

Ketorolac + Ranibizumab — Competitive Intelligence Brief

Ketorolac + Ranibizumab (Ketorolac + Ranibizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + anti-VEGF monoclonal antibody fragment. Area: Ophthalmology.

marketed NSAID + anti-VEGF monoclonal antibody fragment COX enzymes (ketorolac); VEGF-A (ranibizumab) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Ketorolac + Ranibizumab (Ketorolac + Ranibizumab) — Università degli Studi di Brescia. Ketorolac reduces ocular inflammation via COX inhibition while ranibizumab blocks VEGF-A to inhibit pathological neovascularization in the eye.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ketorolac + Ranibizumab TARGET Ketorolac + Ranibizumab Università degli Studi di Brescia marketed NSAID + anti-VEGF monoclonal antibody fragment COX enzymes (ketorolac); VEGF-A (ranibizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + anti-VEGF monoclonal antibody fragment class)

  1. Università degli Studi di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketorolac + Ranibizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/ketorolac-ranibizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: